Practice-Changing Interventions in the Systemic Management of Breast Cancer

Restricted access

Systemic treatment for metastatic breast cancer now incorporates many targeted agents and a plethora of combinations specific to the breast cancer subtype. New to the treatment paradigm are fam-trastuzumab deruxtecan-nxki, and tucatinib for HER2-positive disease; the PI3K inhibitor alpelisib in combination with fulvestrant for estrogen receptor–positive and PIK3CA-mutated tumors; PARP inhibitors for patients with germline BRCA1/2 mutations; and the anti–PD-L1 agent atezolizumab in combination with albumin-bound paclitaxel for triple-negative disease with PD-L1 mutations in tumors. In addition, for estrogen receptor–positive disease, the role of CDK4/6 inhibitors increased substantially during the past year, as overall survival results have emerged. These targeted agents are greatly improving patient outcomes, and thus have all been incorporated into the NCCN Guidelines for Breast Cancer.

Disclosures: Dr. Gradishar has disclosed that he is a scientific advisor for AstraZeneca Pharmaceuticals LP; MacroGenics, Inc.; Roche Laboratories, Inc./Genentech, Inc.; and Seattle Genetics, Inc.

Correspondence: William J. Gradishar, MD, Department of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 North St. Clair Street, Suite 850, Chicago, IL 60611. Email:
  • 1.

    Swain SM, Baselga J, Kim SB, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724734.

  • 2.

    Krop IE, Saura C, Yamashita T, [Fam-] trastuzumab deruxtecan (T-XDd;DS-8021a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: a phase 2, multicenter, open-label study (DESTINY-Breast01) [abstract]. Presented at the 2019 San Antonio Breast Cancer Symposium; December 8–12, 2020; San Antonio, Texas. Abstract GS1-03.

    • Export Citation
  • 3.

    Modi S, Saura C, Yamashita T, Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020;382:610621.

  • 4.

    Murthy RK, Loi S, Okines A, Tucatinib vs placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB) [abstract]. Presented at the 2019 San Antonio Breast Cancer Symposium; December 8–12, 2020; San Antonio, Texas. Abstract GS1-01.

    • Export Citation
  • 5.

    Rugo HS, Im S, Cardoso F, Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis [abstract]. Presented at the 2019 San Antonio Breast Cancer Symposium; December 8–12, 2020; San Antonio, Texas. Abstract GS1-02.

    • Export Citation
  • 6.

    Slamon DJ, Neven P, Chia S, Overall survival results of the phase III MONALEESA-3 trial of postmenopausal patients with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer treated with fulvestrant + ribociclib [abstract]. Presented at the ESMO Congress 2019; September 27–October 1, 2019; Barcelona, Spain. Abstract LBA7.

    • Export Citation
  • 7.

    Sledge GW Jr, Toi M, Neven P, The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA Oncol 2019;6:116124.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Andre F, Ciruelos E, Rubovszky G, Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med 2019;380:19291940.

  • 9.

    Juric D, Ciruelos EM, Rubovszky G, Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): phase 3 SOLAR-1 trial results [abstract]. Presented at the 2018 San Antonio Breast Cancer Symposium; December 4–8, 2018; San Antonio, Texas. Abstract GS3-08.

    • Export Citation
  • 10.

    Robson M, Im SA, Senkus E, Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377:523533.

  • 11.

    Litton JK, Rugo HS, Ettl J, Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018;379:753763.

  • 12.

    Schmid P, Adams S, Rugo HS, Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379:21082121.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 954 954 954
PDF Downloads 288 288 288
EPUB Downloads 0 0 0